Galapagos Genomics NV Licenses MetaCore From GeneGo, Inc.

ST. JOSEPH, Mich., Aug. 1 /PRNewswire/ -- GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Galapagos NV, a genomics-based drug discovery company, will be using the integrated software suite MetaCore for its internal research across several disease areas including osteoporosis, osteoarthritis and rheumatoid arthritis.

"We were satisfied with the demonstrated capabilities and quality of data obtained through MetaCore," commented Dr. Graham Dixon, Senior Vice President of Drug Discovery at Galapagos. "We have already identified and validated novel, proprietary targets using our adenoviral technology platform in bone and joint diseases; applying MetaCore to this target set could allow us to gain valuable insights at the system level thereby improving our understanding of the underlying disease biology and increasing our speed and success in finding new drugs against these targets."

"We are very pleased to welcome Galapagos as a new customer," said Julie Bryant, Vice President of Business Development at GeneGo. "Over the last year, systems analysis of biological data has become mainstream, rather than a niche application, for high volume high throughput genomics labs. The new customization tools and expansion of knowledge content in disease areas make MetaCore applicable for focused research programs at specialized drug discovery companies. We are proud that Galapagos has selected MetaCore in the competitive market of pathways tools."

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, siRNA and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.0, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at www.genego.com.

MetaCore(TM), MetaBase(TM) and MetaDrug(TM) are trademarks of GeneGo, Inc.

CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo,Inc., +1-858-756-7996, julie@genego.com

Web site: http://www.genego.com//